Press Release: Sanofi and Seagen announce collaboration to develop
and commercialize multiple novel antibody-drug conjugates
Sanofi and Seagen announce collaboration to develop and
commercialize multiple novel antibody-drug conjugates
- Jointly fund and develop up to
three antibody-drug conjugate programs for the treatment of
cancer
Paris,
March 16,
2022. Sanofi and Seagen Inc.
(Nasdaq:SGEN) today announced an exclusive collaboration agreement
to design, develop, and commercialize antibody-drug conjugates
(ADCs) for up to three cancer targets. The collaboration will
utilize Sanofi’s proprietary monoclonal antibody (mAb) technology
and Seagen’s proprietary ADC technology. ADCs are
antibodies engineered to deliver potent anti-cancer
drugs to tumor cells expressing a specific protein and Sanofi
currently has one ADC in development.
John Reed,
M.D.,
Ph.D.Global
Head of Research and Development, Sanofi“This collaboration will
enable the synergistic combination of molecules and platforms to
produce candidate medicines with the potential of bringing renewed
hope to cancer patients and their families. We look forward to
joining forces with Seagen to collaboratively design and develop
promising medicines by advancing antibody-drug conjugate
science.”
Clay
Siegall,
Ph.D.President
and Chief Executive Officer, Seagen“We are excited to be working
with Sanofi, a global biopharmaceutical leader, to identify new
ways to potentially address unmet medical needs of cancer patients.
Jointly developing novel ADCs by combining antibodies from Sanofi
with Seagen’s proprietary ADC technology, aligns with our strategic
priorities to expand the global potential of our pipeline with new
first- or best-in-class programs.”
Under the terms of the collaboration, Seagen and
Sanofi will co-fund global development activities and share equally
in any future profits. In addition, Sanofi will make an undisclosed
payment to Seagen for each of the three targets as they are
selected. The first target under the collaboration has already been
designated.
About SeagenSeagen is a global biotechnology
company that discovers, develops and commercializes transformative
cancer medicines to make a meaningful difference in people’s lives.
Seagen is headquartered in the Seattle, Washington area, and has
locations in California, Canada, Switzerland and the European
Union. For more information on the company’s marketed products and
robust pipeline, visit www.seagen.com and follow @SeagenGlobal on
Twitter.
About Sanofi
We are an innovative global healthcare company,
driven by one purpose: we chase the miracles of science to improve
people’s lives. Our team, across some 100 countries, is dedicated
to transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing
treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social
responsibility at the center of our ambitions. Sanofi is listed on
EURONEXT: SAN and NASDAQ: SNY
Sanofi Contacts
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69
36 93 | arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comPriya Nanduri | +1
908 981 5560 | priya.nanduri@sanofi.com Nathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Seagen Contacts
For InvestorsPeggy
PinkstonSenior Vice President, Investor Relations(425)
527-4160ppinkston@seagen.com
For MediaDavid CaouetteVice
President, Corporate Communications(310)
430-3476dcaouette@seagen.com
Seagen Forward-Looking
Statements Certain of the statements made in this press
release are forward looking, such as those relating to potential
design, development and commercialization efforts, efforts to
identify new ways to address unmet medical needs, and other
statements that are not historical facts. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the difficulty and uncertainty of pharmaceutical
product development, the risk of adverse events or safety signals,
the inability to show sufficient activity in clinical trials, the
possibility of adverse regulatory actions and risk related to the
COVID-19 pandemic. More information about the risks and
uncertainties faced by Seagen is contained under the caption “Risk
Factors” included in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2021 filed with the Securities and
Exchange Commission. Seagen disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2021. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Sanofi (BIT:1SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024